Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 630

Results For "GE"

8420 News Found

OS-SiA digital pathology scanner developed by OptraSCAN granted US patent
Biotech | May 30, 2022

OS-SiA digital pathology scanner developed by OptraSCAN granted US patent

OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights


North India’s first biotech park at Kathua, J&K inaugurated
News | May 30, 2022

North India’s first biotech park at Kathua, J&K inaugurated

Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas


NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)
News | May 30, 2022

NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)

The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level


USFDA approves two Opdivo-based regimens
Biotech | May 29, 2022

USFDA approves two Opdivo-based regimens

Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers


JBCL rebrands as JB
News | May 29, 2022

JBCL rebrands as JB

JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India


Medisca inks distribution license with SUANFARMA
Biotech | May 29, 2022

Medisca inks distribution license with SUANFARMA

Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price


Venus Remedies registers 9.22 % growth in annual sales for FY22
News | May 29, 2022

Venus Remedies registers 9.22 % growth in annual sales for FY22

The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal


USFDA approves Novartis Kymriah CAR-T cell therapy
Biotech | May 29, 2022

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile


All India Institute of Ayurveda launches #YogaSeAyu campaign for International Day of Yoga 2022
Healthcare | May 29, 2022

All India Institute of Ayurveda launches #YogaSeAyu campaign for International Day of Yoga 2022

The campaign aims to promote an integrated view by combining Ayurveda and Yoga to create harmony not just within the body, but also in our minds


Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Biotech | May 27, 2022

Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis

Data from the three studies formed the basis of the company's application for approval by regulatory agencies